Dillon Harding Miles

This inventor holds 19 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 6 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Arcus Biosciences, Inc., Other. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dillon Harding Miles. Retrieved from https://idiyas.com/inventor/dillon-harding-miles

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 6)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 6 (Patent Applications = 15)

Average Co-Inventor Count = 7.4

ph-index = 4

Forward Citations = 74(Granted Patents)

Company Filing History:

18 out of 40

Arcus Biosciences, Inc.

patents

1 out of 834,570

Other

patents

Years Active: 2019-2026

Loading Chart...

Areas of Expertise:

Aminopyrimidine

5'-Nucleotidase

Pyrazolo

Azolopyrimidine

AXL Inhibitors

CD73 Inhibitors

Cancer Treatment

Quinazoline Derivatives

Pyridone A2R

Immunosuppression

Trisubstituted Compounds

Solid Forms

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12630526 - Processes for preparing aminopyrimidine compounds (2026-05-19),

2. 12459967 - Modulators of 5'-nucleotidase, ecto and the use thereof (2025-11-04),

3. 12410170 - 2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds (2025-09-09),

4. 12195482 - Compounds as inhibitors of AXL (2025-01-14),

5. 12195447 - Azolopyrimidine for the treatment of cancer-related disorders (2025-01-14),

6. 12168023 - Inhibitors of adenosine 5'-nucleotidase (2024-12-17),

7. 12064433 - Pyridone A2R antagonists (2024-08-20),

8. 11993584 - Solid forms of an azolopyrimidine compound (2024-05-28),

9. 11819512 - Solid forms of a CD73 inhibitor and the use thereof (2023-11-21),

10. 11667662 - Modulators of 5'-nucleotidase, ecto and the use thereof (2023-06-06),

11. 11267845 - Inhibitors of CD73-mediated immunosuppression (2022-03-08),

12. 11220492 - Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders (2022-01-11),

13. 11072597 - Azolopyrimidine for the treatment of cancer-related disorders (2021-07-27),

14. 11058704 - Inhibitors of adenosine 5'-nucleotidase (2021-07-13),

15. 11045472 - Quinazoline-pyridine derivatives for the treatment of cancer-related disorders (2021-06-29),

Title: Dillon Harding Miles: Innovator in Pharmaceutical Compounds

Introduction

Dillon Harding Miles is a prominent inventor based in Berkeley, CA, known for his significant contributions to the field of pharmaceutical compounds. With a total of 17 patents to his name, he has made remarkable strides in developing innovative treatments for various diseases.

Latest Patents

Miles' latest patents include groundbreaking compounds such as 2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine, which inhibit PI3Kγ. These compounds and their compositions are designed for the treatment of a diverse array of diseases, including cancer and immune-related disorders. Another notable patent involves azolopyrimidine, which serves as an inhibitor of adenosine receptors, also aimed at treating cancer-related disorders.

Career Highlights

Throughout his career, Dillon has worked with notable companies, including Arcus Biosciences, Inc. His work has focused on synthesizing compounds that address critical health issues, showcasing his dedication to advancing medical science.

Collaborations

Miles has collaborated with esteemed colleagues such as Manmohan Reddy Leleti and Jay Patrick Powers, contributing to the development of innovative solutions in the pharmaceutical industry.

Conclusion

Dillon Harding Miles stands out as a key figure in the realm of pharmaceutical innovation, with a strong portfolio of patents that reflect his commitment to improving health outcomes through scientific advancements.

Profile summary based on public USPTO records.